Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2323 studies found for:    EGFR
Show Display Options
Rank Status Study
1 Recruiting Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
Condition: Advanced EGFR-positive Solid Tumors
Intervention: Biological: CART-EGFR
2 Unknown  Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
Condition: NSCLC
Intervention: Other: cancer cell lines establishment
3 Completed
Has Results
Asia Pacific and Russia Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention: Genetic: EGFR mutation test
4 Recruiting CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Condition: Advanced Glioma
Intervention: Biological: anti-EGFR CAR T
5 Recruiting Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
Conditions: Non-Small Cell Lung Cancer;   Brain Metastases;   EGFR Gene Mutation
Interventions: Drug: Gefitinib;   Radiation: WBRT
6 Unknown  Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Condition: EGFR Mutation Positive Non-small Cell Lung Cancer
Intervention: Drug: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
7 Recruiting Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: anti-EGFR-IL-dox
8 Completed Anti-EGFR Immunoliposomes in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: anti-EGFR immunoliposomes loaded with doxorubicin
9 Completed Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis
Conditions: Gastroesophageal Reflux Disease;   Chronic Laryngitis
Interventions: Procedure: Biopsy of the retrocrycoid laryngeal mucosa;   Procedure: Biopsy of the distal esophageal mucosa
10 Active, not recruiting Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Conditions: Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head And Neck
Intervention: Biological: EGFR Antisense DNA
11 Not yet recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Conditions: Glioblastoma;   Astrocytoma, Grade IV
Intervention: Drug: EGFR(V)-EDV-Dox
12 Active, not recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
13 Completed Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
Condition: NSCLC Non Small Cells Lung Cancer
Intervention:
14 Not yet recruiting A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
Conditions: Lung Adenocarcinoma;   EGFR Positive Non-small Cell Lung Cancer
Interventions: Drug: EGFR-TKI;   Radiation: Thoracic Hypofractionated Radiotherapy
15 Recruiting EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: EGFR Activating Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Necitumumab;   Drug: Osimertinib;   Other: Pharmacological Study
16 Unknown  A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Condition: Plaque Psoriasis
Interventions: Drug: Human recombinant epidermal growth factor;   Other: Placebo cream
17 Not yet recruiting EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
Condition: Non-small Cell Lung Cancer
Intervention:
18 Not yet recruiting Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)
Conditions: Non Small Cell Lung Cancer;   EGFR-TKI Resistant Mutation;   EGFR-TKI Sensitizing Mutation
Intervention:
19 Active, not recruiting Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Condition: EGFR Inhibitor-associated Rash
Intervention: Drug: Menadione Topical Lotion
20 Not yet recruiting Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Condition: Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Intervention: Drug: Chidamide with EGFR-TKI

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.